{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:43:55Z","timestamp":1793943835681,"version":"4.8.0"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.neuropharm.2022.108948","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:27:08Z","timestamp":1642033628000},"page":"108948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Cannabidiol and substance use disorder: Dream or reality"],"prefix":"10.1016","volume":"207","author":[{"given":"Saeideh","family":"Karimi-Haghighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-4548","authenticated-orcid":false,"given":"Daniela","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Scheyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-180X","authenticated-orcid":false,"given":"Abbas","family":"Haghparast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.108948_bib1","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1172\/JCI83817","article-title":"Phosphorylation state-dependent modulation of spinal glycine receptors alleviates inflammatory pain","volume":"126","author":"Acu\u00f1a","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.108948_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brainres.2012.01.030","article-title":"The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats","volume":"1444","author":"Adamczyk","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of cannabidiol, a product isolated from the Marihuana extract of Minnesota wild hemp. I","volume":"62","author":"Adams","year":"1940","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2022.108948_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib5","article-title":"Cannabidiol efficiently suppressed the acquisition and expression of methamphetamine-induced conditioned place preference in the rat","volume":"113158","author":"Anooshe","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.108948_bib7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA(A) receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/sj.bjp.0704829","article-title":"Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site","volume":"137","author":"Barann","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0706743720926798","article-title":"Cannabidiol for mood disorders: a call for more research","volume":"66","author":"Bartoli","year":"2021","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/can.2017.0047","article-title":"Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users","volume":"3","author":"Beale","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.neuropharm.2022.108948_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00426828","article-title":"Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice","volume":"49","author":"Bhargava","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.neuropharm.2009.01.007","article-title":"Deletion of vanilloid receptor (TRPV1) in mice alters behavioral effects of ethanol","volume":"56","author":"Blednov","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.108948_bib16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00003643-200206000-00002","article-title":"Pathophysiology of cocaine abuse","volume":"19","author":"Brownlow","year":"2002","journal-title":"Eur. J. Anaesthesiol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","article-title":"Cannabidiol (CBD) and its analogs: a review of their effects on inflammation","volume":"23","author":"Burstein","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.108948_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24142583","article-title":"Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: a review of possible mechanisms","volume":"24","author":"Calpe-L\u00f3pez","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2022.108948_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/0269881120965952","article-title":"Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice","author":"Calpe-L\u00f3pez","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2022.108948_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0091-3057(85)90122-4","article-title":"The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol","volume":"23","author":"Chesher","year":"1985","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.108948_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.173065","article-title":"Cannabidiol (CBD) reduces cocaine-environment memory in mice","volume":"199","author":"Chesworth","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.108948_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028142","article-title":"Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition","volume":"6","author":"Cippitelli","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.108948_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0090-9556(25)07765-7","article-title":"The metabolism and excretion of buprenorphine in humans","volume":"12","author":"Cone","year":"1984","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2022.108948_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00431988","article-title":"Interaction of cannabidiol and alcohol in humans","volume":"66","author":"Consroe","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s13311-017-0525-z","article-title":"Reward circuitry in addiction","volume":"14","author":"Cooper","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.108948_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jcpt.12018","article-title":"Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report","volume":"38","author":"Crippa","year":"2013","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.108948_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \"Pipeline\" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.108948_bib33","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/adb.12366","article-title":"Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in Wistar rats","volume":"22","author":"De Carvalho","year":"2017","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/npp.2014.268","article-title":"PPAR\u03b3 activation attenuates opioid consumption and modulates mesolimbic dopamine transmission","volume":"40","author":"De Guglielmo","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib35","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","article-title":"Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation","volume":"204","author":"De Petrocellis","year":"2012","journal-title":"Acta Physiol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/jpet.107.134809","article-title":"Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8","volume":"325","author":"De Petrocellis","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.108948_bib38","first-page":"242","article-title":"Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol","volume":"114","author":"Demirakca","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.108948_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.108948_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.06.005","article-title":"Effects of cannabidiol (CBD) in neuropsychiatric disorders: a review of pre-clinical and clinical findings","volume":"167","author":"Elsaid","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fnmol.2017.00200","article-title":"Direct anandamide activation of TRPV1 produces divergent calcium and current responses","volume":"10","author":"Fenwick","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review","volume":"107","author":"Freeman","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.108948_bib43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1310\/hpj4806-473","article-title":"The federal controlled substances act: schedules and pharmacy registration","volume":"48","author":"Gabay","year":"2013","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.neuropharm.2022.108948_bib45","doi-asserted-by":"crossref","first-page":"107740","DOI":"10.1016\/j.neuropharm.2019.107740","article-title":"Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT(1A) and TRPV1 receptor mechanisms","volume":"167","author":"Galaj","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib46","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2022.108948_bib47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.20882\/adicciones.862","article-title":"Animal models of drug addiction","volume":"29","author":"Garc\u00eda Pardo","year":"2017","journal-title":"Adicciones"},{"key":"10.1016\/j.neuropharm.2022.108948_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000324065","article-title":"Addiction and brain reward and antireward pathways","volume":"30","author":"Gardner","year":"2011","journal-title":"Adv. Psychosom. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108948_bib49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s13311-020-00976-6","article-title":"Cannabidiol modulates behavioural and gene expression alterations induced by spontaneous cocaine withdrawal","volume":"18","author":"Gasparyan","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.108948_bib50","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/sj.npp.1301648","article-title":"Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant","volume":"33","author":"Gerdeman","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib51","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle","volume":"43","author":"Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/schbul\/sbx105","article-title":"The potential of cannabidiol treatment for cannabis users with recent-onset psychosis","volume":"44","author":"Hahn","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2022.108948_bib53","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brainresbull.2021.04.007","article-title":"Cannabidiol modulates the METH-induced conditioned place preference through D2-like dopamine receptors in the hippocampal CA1 region","volume":"172","author":"Hassanlou","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.108948_bib55","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/0269881118799954","article-title":"Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats","volume":"32","author":"Hay","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104546","article-title":"Blocking TRPV1 in nucleus accumbens inhibits persistent morphine conditioned place preference expression in rats","volume":"9","author":"Heng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.108948_bib57","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1038\/s41598-018-25846-2","article-title":"The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers","volume":"8","author":"Hindocha","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.108948_bib58","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal","volume":"113","author":"Hindocha","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2022.108948_bib59","first-page":"185","article-title":"Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats","volume":"12","author":"Hine","year":"1975","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tins.2016.12.006","article-title":"Cannabidiol: swinging the marijuana pendulum from 'weed' to medication to treat the opioid epidemic","volume":"40","author":"Hurd","year":"2017","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib61","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.108948_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0304-3940(88)90691-X","article-title":"Quantitative analysis of the distribution of serotonin-immunoreactive cell bodies in the mouse brain","volume":"91","author":"Ishimura","year":"1988","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.108948_bib65","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc16-0650","article-title":"Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study","volume":"39","author":"Jadoon","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuropharm.2022.108948_bib66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pbb.2017.10.002","article-title":"Pioglitazone, a PPAR\u03b3 agonist, reduces nicotine craving in humans, with marginal effects on abuse potential","volume":"163","author":"Jones","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"Suppl","key":"10.1016\/j.neuropharm.2022.108948_bib67","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.brainres.2009.09.053","article-title":"Glycine receptor expression in the forebrain of male AA\/ANA rats","volume":"1305","author":"Jonsson","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2012.01.050","article-title":"Changes in glycine receptor subunit expression in forebrain regions of the Wistar rat over development","volume":"1446","author":"Jonsson","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12740","article-title":"Cannabidiol modulates the expression of neuroinflammatory factors in stress- and drug-induced reinstatement of methamphetamine in extinguished rats","volume":"25","author":"Karimi-Haghighi","year":"2020","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pnpbp.2017.08.022","article-title":"Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats","volume":"82","author":"Karimi-Haghighi","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib71","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib72","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1369-1600.2012.00483.x","article-title":"Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus","volume":"18","author":"Katsidoni","year":"2013","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib73","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jpsychires.2021.02.045","article-title":"Cannabidiol enhanced the development of sensitization to the expression of methamphetamine-induced conditioned place preference in male rats","volume":"137","author":"Khanegheini","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib74","first-page":"88","article-title":"The health effects of cannabis and cannabinoids","volume":"15","author":"Klimkiewicz","year":"2018","journal-title":"Psychiatria"},{"key":"10.1016\/j.neuropharm.2022.108948_bib75","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-3565(25)30726-3","article-title":"Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain","volume":"199","author":"Koe","year":"1976","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.108948_bib76","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1476-5381.2011.01379.x","article-title":"Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL\/6 mice","volume":"163","author":"Kozela","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1300\/J069v26n04_10","article-title":"Physician awareness of the cardiac effects of methadone: results of a national survey","volume":"26","author":"Krantz","year":"2007","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neuropharm.2022.108948_bib78","first-page":"93","article-title":"What is addiction?","volume":"31","author":"Kranzler","year":"2008","journal-title":"Alcohol Res. Health"},{"key":"10.1016\/j.neuropharm.2022.108948_bib79","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14737175.2021.1834383","article-title":"Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome","volume":"21","author":"Lattanzi","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2022.108948_bib81","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.0711278105","article-title":"GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current","volume":"105","author":"Lauckner","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.108948_bib82","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02862859","article-title":"An archaeological and historical account of cannabis in China","volume":"28","author":"Li","year":"1974","journal-title":"Econ. Bot."},{"key":"10.1016\/j.neuropharm.2022.108948_bib84","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2022.108948_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib86","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib87","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib88","article-title":"CB1 receptor antagonist AM4113 reverts the effects of cannabidiol on cue and stress-induced reinstatement of cocaine-seeking behaviour in mice","author":"Luj\u00e1n","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib89","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12778","article-title":"The pharmacological reduction of hippocampal neurogenesis attenuates the protective effects of cannabidiol on cocaine voluntary intake","volume":"25","author":"Luj\u00e1n","year":"2020","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuropharm.2018.09.043","article-title":"Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus","volume":"143","author":"Luj\u00e1n","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1101\/lm.037317.114","article-title":"Reward processing by the dorsal raphe nucleus: 5-HT and beyond","volume":"22","author":"Luo","year":"2015","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2022.108948_bib92","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.bjp.0705931","article-title":"Marijuana and cannabinoid regulation of brain reward circuits","volume":"143","author":"Lupica","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib93","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.108948_bib94","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.npp.1301213","article-title":"Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice","volume":"32","author":"Maeda","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib95","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejphar.2013.10.011","article-title":"Effects of cannabidiol on the function of \u03b17-nicotinic acetylcholine receptors","volume":"720","author":"Mahgoub","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/0269881116667706","article-title":"Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats","volume":"31","author":"Mahmud","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S2045796018000239","article-title":"Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview","volume":"27","author":"Mandolini","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib98","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J. Addiction Med."},{"key":"10.1016\/j.neuropharm.2022.108948_bib99","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.psc.2012.03.012","article-title":"Psychostimulant treatment of cocaine dependence","volume":"35","author":"Mariani","year":"2012","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.neuropharm.2022.108948_bib100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0043-117838","article-title":"Effects of cannabidiol on morphine conditioned place preference in mice","volume":"84","author":"Markos","year":"2018","journal-title":"Planta Med."},{"key":"10.1016\/j.neuropharm.2022.108948_bib101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/sni.sni_45_18","article-title":"Review of the neurological benefits of phytocannabinoids","volume":"9","author":"Maroon","year":"2018","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.neuropharm.2022.108948_bib102","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1523\/JNEUROSCI.3303-06.2007","article-title":"Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice","volume":"27","author":"Marsch","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib103","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib104","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB(2) receptors","volume":"8","author":"Mart\u00ednez-Pinilla","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2022.108948_bib106","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1055\/s-2004-832678","article-title":"Involvement of the sigma1 receptor in the appetitive effects of cocaine","volume":"37","author":"Maurice","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib107","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.celrep.2014.08.037","article-title":"Serotonergic versus nonserotonergic dorsal raphe projection neurons: differential participation in reward circuitry","volume":"8","author":"McDevitt","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2022.108948_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.169.3945.611","article-title":"Chemical basis of hashish activity","volume":"169","author":"Mechoulam","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.108948_bib110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.biopsych.2010.04.016","article-title":"Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors","volume":"68","author":"Melis","year":"2010","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib111","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000341719","article-title":"Cocaine-related health emergencies in Europe: a review of sources of information, trends and implications for service development","volume":"19","author":"Mena","year":"2013","journal-title":"Eur. Addiction Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib112","article-title":"Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study","author":"Meneses-Gaya","year":"2020","journal-title":"Braz. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euroneuro.2021.04.008","article-title":"Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats","volume":"50","author":"Metz","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.108948_bib114","first-page":"34","article-title":"Marijuana in medicine: past, present and future","volume":"110","author":"Mikuriya","year":"1969","journal-title":"Calif. Med."},{"key":"10.1016\/j.neuropharm.2022.108948_bib115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/adb.12471","article-title":"PPAR\u03b3 agonism attenuates cocaine cue reactivity","volume":"23","author":"Miller","year":"2018","journal-title":"Addiction Biol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.108948_bib116","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/add.15417","article-title":"Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial","volume":"116","author":"Mongeau-P\u00e9russe","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2022.108948_bib117","first-page":"103","article-title":"Molecular targets of the phytocannabinoids: a complex picture","volume":"103","author":"Morales","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"10.1016\/j.neuropharm.2022.108948_bib118","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2003.08.064","article-title":"Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS","volume":"123","author":"Moreno","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.108948_bib120","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2022.108948_bib121","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pneurobio.2007.01.001","article-title":"Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors","volume":"81","author":"M\u00fcller","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib122","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.108948_bib123","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.lfs.2011.01.013","article-title":"Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats","volume":"88","author":"Murillo-Rodr\u00edguez","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib124","doi-asserted-by":"crossref","first-page":"15894","DOI":"10.1074\/jbc.M608287200","article-title":"Activation properties of heterologously expressed mammalian TRPV2: evidence for species dependence","volume":"282","author":"Neeper","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.108948_bib125","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1038\/npp.2014.90","article-title":"Transient receptor potential vanilloid type 1 channel may modulate opioid reward","volume":"39","author":"Nguyen","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib126","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1037\/pha0000272","article-title":"Effects of cannabidiol on alcohol-related outcomes: a review of preclinical and human research","volume":"27","author":"Nona","year":"2019","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.108948_bib127","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-021-03350-w","article-title":"Involvement of hippocampal D1-like dopamine receptors in the inhibitory effect of cannabidiol on acquisition and expression of methamphetamine-induced conditioned place preference","volume":"46","author":"Nouri","year":"2021","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib128","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1213\/ANE.0b013e318204ea5b","article-title":"Capsaicin indirectly suppresses voltage-gated Na+ currents through TRPV1 in rat dorsal root ganglion neurons","volume":"112","author":"Onizuka","year":"2011","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2022.108948_bib129","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cpt.118","article-title":"Cannabinoid abuse and addiction: clinical and preclinical findings","volume":"97","author":"Panlilio","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.108948_bib130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","article-title":"Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats","volume":"175","author":"Parker","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib131","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib132","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neubiorev.2005.04.016","article-title":"The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?","volume":"30","author":"Pierce","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.108948_bib133","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12640-020-00218-9","article-title":"Cannabidiol prevents the expression of the locomotor sensitization and the metabolic changes in the nucleus accumbens and prefrontal cortex elicited by the combined administration of cocaine and caffeine in rats","volume":"38","author":"Prieto","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib134","first-page":"33","article-title":"Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence","volume":"9","author":"Prud'homme","year":"2015","journal-title":"Subst. Abuse"},{"key":"10.1016\/j.neuropharm.2022.108948_bib135","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","article-title":"TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons","volume":"28","author":"Qin","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neubiorev.2014.11.005","article-title":"Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications","volume":"48","author":"Rajasekaran","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.108948_bib137","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/npp.2012.269","article-title":"Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice","volume":"38","author":"Ramesh","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib138","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/FBP.0000000000000544","article-title":"Neuroprotective effect of chronic administration of cannabidiol during the abstinence period on methamphetamine-induced impairment of recognition memory in the rats","volume":"31","author":"Razavi","year":"2020","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib139","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib140","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1523\/JNEUROSCI.3387-15.2016","article-title":"Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR\/p70S6 kinase signaling pathway","volume":"36","author":"Renard","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib141","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/15563650.2016.1142090","article-title":"Treatment of cocaine cardiovascular toxicity: a systematic review","volume":"54","author":"Richards","year":"2016","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172982","article-title":"Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: a systematic review","volume":"196","author":"Rodrigues","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.108948_bib143","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(67)90084-2","article-title":"Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents","volume":"2","author":"Ross","year":"1967","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib144","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0014-2999(69)90091-0","article-title":"Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue","volume":"7","author":"Ross","year":"1969","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neuroscience.2017.03.019","article-title":"Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: reduced dopaminergic modulation and immediate gene expression in limbic circuits","volume":"350","author":"Rossignoli","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.108948_bib146","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.tips.2016.04.005","article-title":"Beyond cannabis: plants and the endocannabinoid system","volume":"37","author":"Russo","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib147","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnint.2018.00051","article-title":"Cannabis therapeutics and the future of neurology","volume":"12","author":"Russo","year":"2018","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib148","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.03.014","article-title":"Cannabidiol: a review of clinical efficacy and safety in epilepsy","volume":"96","author":"Samanta","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.neuroscience.2007.10.026","article-title":"Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons","volume":"151","author":"Sano","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.108948_bib151","series-title":"Neurobiology of TRP Channels","author":"Sawamura","year":"2019"},{"key":"10.1016\/j.neuropharm.2022.108948_bib152","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41401-018-0075-x","article-title":"Brain activity of anandamide: a rewarding bliss?","volume":"40","author":"Scherma","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2022.108948_bib153","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/add.13868","article-title":"PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial","volume":"112","author":"Schmitz","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2022.108948_bib154","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YCO.0000000000000596","article-title":"Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies","volume":"33","author":"Schoevers","year":"2020","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib155","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1007\/s00213-018-4986-5","article-title":"Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder","volume":"235","author":"Schroeder","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib156","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phytother Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib157","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib158","article-title":"Cannabidiol impairs the rewarding effects of methamphetamine: involvement of dopaminergic receptors in the nucleus accumbens","author":"Sharifi","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib159","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.chc.2016.03.002","article-title":"Opioid use disorders","volume":"25","author":"Sharma","year":"2016","journal-title":"Child Adolesc. Psychiatr. Clin. N Am."},{"key":"10.1016\/j.neuropharm.2022.108948_bib160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/09595230801927372","article-title":"The principles of agonist pharmacotherapy for psychostimulant dependence","volume":"27","author":"Shearer","year":"2008","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.neuropharm.2022.108948_bib161","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.japh.2019.11.008","article-title":"Use of cannabidiol in anxiety and anxiety-related disorders","volume":"60","author":"Skelley","year":"2020","journal-title":"J. Am. Pharmaceut. Assoc."},{"key":"10.1016\/j.neuropharm.2022.108948_bib162","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised \u0394(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib163","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib164","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","article-title":"Animal models of addiction","volume":"19","author":"Spanagel","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107937","article-title":"Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users","volume":"211","author":"Spindle","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.108948_bib166","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2010.12.010","article-title":"Activation of nuclear PPAR\u03b3 receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking","volume":"69","author":"Stopponi","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib167","first-page":"G1180","article-title":"Capsaicin sensitivity and voltage-gated sodium currents in colon sensory neurons from rat dorsal root ganglia","volume":"277","author":"Su","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib168","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","article-title":"Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol","volume":"95","author":"Szaflarski","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2022.108948_bib169","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2022.108948_bib170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2010.01.058","article-title":"Repeated methamphetamine treatment increases expression of TRPV1 mRNA in the frontal cortex but not in the striatum or hippocampus of mice","volume":"472","author":"Tian","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.108948_bib171","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s41598-018-19207-2","article-title":"Blockade of TRPV1 inhibits methamphetamine-induced rewarding effects","volume":"8","author":"Tian","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.108948_bib172","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02791072.1981.10471447","article-title":"The religious and medicinal uses of Cannabis in China, India and Tibet","volume":"13","author":"Touw","year":"1981","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2022.108948_bib173","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/ADM.0000000000000229","article-title":"Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a case series","volume":"10","author":"Trigo","year":"2016","journal-title":"J. Addiction Med."},{"key":"10.1016\/j.neuropharm.2022.108948_bib174","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/can.2015.0012","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy","volume":"1","author":"Ujv\u00e1ry","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuropharm.2022.108948_bib176","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.141","article-title":"Involvement of PPAR\u03b3 in the antitumoral action of cannabinoids on hepatocellular carcinoma","volume":"4","author":"Vara","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2022.108948_bib177","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2018.05.031","article-title":"Intra-accumbal administration of AMN082, a metabotropic glutamate receptor type 7 allosteric agonist, inhibits the acquisition but not the expression of morphine-induced conditioned place preference in rats","volume":"681","author":"Vatankhah","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.108948_bib178","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0022-5347(25)00276-9","article-title":"Modulation of rat brain opioid receptors by cannabinoids","volume":"241","author":"Vaysse","year":"1987","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.108948_bib179","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0028-3908(95)00032-2","article-title":"Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine","volume":"34","author":"Vela","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.108948_bib180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/adb.12495","article-title":"Cannabidiol reduces ethanol consumption, motivation and relapse in mice","volume":"23","author":"Viudez-Mart\u00ednez","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib181","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cell.2015.07.046","article-title":"The brain on drugs: from reward to addiction","volume":"162","author":"Volkow","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.108948_bib182","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn.2017.130","article-title":"The dopamine motive system: implications for drug and food addiction","volume":"18","author":"Volkow","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib183","article-title":"Opioid addiction, genetic susceptibility, and medical treatments: a review","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib184","doi-asserted-by":"crossref","first-page":"18142","DOI":"10.1074\/jbc.M501229200","article-title":"Transient receptor potential vanilloid type 1 activation down-regulates voltage-gated calcium channels through calcium-dependent calcineurin in sensory neurons","volume":"280","author":"Wu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.108948_bib185","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nchembio.552","article-title":"Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia","volume":"7","author":"Xiong","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib186","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/toxres\/tfaa021","article-title":"Cannabidiol attenuates methamphetamine-induced conditioned place preference via the Sigma1R\/AKT\/GSK-3\u03b2\/CREB signaling pathway in rats","volume":"9","author":"Yang","year":"2020","journal-title":"Toxicol. Res. (Camb.)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib187","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1523\/JNEUROSCI.2016-04.2004","article-title":"Presynaptic glycine receptors on GABAergic terminals facilitate discharge of dopaminergic neurons in ventral tegmental area","volume":"24","author":"Ye","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib188","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.201","article-title":"Hippocampal harms, protection and recovery following regular cannabis use","volume":"6","author":"Y\u00fccel","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.108948_bib189","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/archpsyc.65.6.694","article-title":"Regional brain abnormalities associated with long-term heavy cannabis use","volume":"65","author":"Y\u00fccel","year":"2008","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib190","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib191","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11481-018-9782-9","article-title":"Cannabis addiction and the brain: a review","volume":"13","author":"Zehra","year":"2018","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108948_bib192","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00213-017-4691-9","article-title":"Blockade of alcohol escalation and \"relapse\" drinking by pharmacological FAAH inhibition in male and female C57BL\/6J mice","volume":"234","author":"Zhou","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.108948_bib193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-neuro-070815-014038","article-title":"Beyond the CB1 receptor: is cannabidiol the answer for disorders of motivation?","volume":"39","author":"Zlebnik","year":"2016","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.108948_bib194","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","article-title":"History of cannabis as a medicine: a review","volume":"28","author":"Zuardi","year":"2006","journal-title":"Braz. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.108948_bib195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson's disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:16:29Z","timestamp":1758438989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":195,"alternative-id":["S0028390822000077"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108948","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol and substance use disorder: Dream or reality","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108948"}}